• Female subject age 40 to 50 years, inclusive

• Suffering from the symptom of heavy menstrual bleeding (HMB) from benign causes with no definable organic cause and are candidates for endometrial ablation or surgical treatment.

• PBAC score of \>150 - an average of 2 consecutive screening scores prior to study treatment

• Are thought to be ovulatory with cyclic predictable onset of menses with a cycle length of 24-38 days.

• Have either a normal appearing endometrial cavity as assessed by hysteroscopy performed within 90 days of study treatment, or one that is distorted by a FIGO Type 2 submucous leiomyoma ≤3 cm in mean diameter.

• Have endometrial sampling with normal histology within 6 months of the study procedure.

• Premenopausal status confirmed by FSH level measurement at screening (FSH \< 40 IU/L). FSH level measurement will be repeated in case of a borderline result

• Screening hemoglobin levels \>9.0 g/dL

• Uterine sound measurement of 6.5-12 cm (external os to internal fundus)

⁃ Negative serum pregnancy test at the Screening visit and on the day of SEAD™ treatment

⁃ women whose sexual activity places them at risk for pregnancy must agree to use an effective, non-hormonal, non-intrauterine method of contraception throughout the course of the study. For this study, acceptable effective methods of contraception are considered to be those listed below:

∙ Barrier method, i.e., (a) condom (male or female) with spermicide or (b) diaphragm with spermicide or

‣ Vasectomy (partner), or

‣ Abstinence, if in line with the preferred and usual lifestyle of the subject \[where abstinence is defined as refraining from heterosexual intercourse\]

⁃ Subject is able to understand and sign a written informed consent form

⁃ Subject is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

⁃ The subject demonstrates an understanding of how to record menstrual blood loss using a menstrual pictogram